Astellas(US:ALPMY) Sou Hu Wang·2025-05-29 02:04Core Insights - The ARCHES trial's five-year follow-up data indicates that enzalutamide combined with androgen deprivation therapy (ADT) reduces the risk of death by 30% in patients with metastatic hormone-sensitive prostate cancer (mHSPC) [1][2] - The five-year survival rate for patients receiving enzalutamide with ADT is 66%, compared to 53% for the placebo group [1] - Enzalutamide is the first and only androgen receptor inhibitor to demonstrate a five-year overall survival benefit in mHSPC patients [1] Group 1: Clinical Efficacy - The five-year follow-up shows a 13% absolute increase in survival rate compared to standard hormone therapy, with a relative survival improvement of 30% [2] - Significant clinical benefits were observed across various patient subgroups, including those with high tumor burden and those who had not previously received docetaxel treatment [2] - In high tumor burden patients, the median overall survival (OS) improved by 36 months [2] Group 2: Safety and Tolerability - The incidence of adverse events during treatment was consistent with previous ARCHES analyses, with no new safety signals identified [2] Group 3: Research and Development - The five-year results from the ARCHES study will be presented at the American Society of Clinical Oncology (ASCO) annual meeting [1] - Additional data from the ENZAMET study, which evaluates enzalutamide versus non-steroidal anti-androgens (NSAA) in mHSPC, will also be showcased [3][4] Group 4: Market Position - Enzalutamide has been approved in over 90 countries, with more than 1 million patients treated globally since its first approval in 2012 [5] - The ongoing research and accumulating data further solidify enzalutamide's long-term efficacy and patient benefits in advanced prostate cancer treatment [3][4]